Overview

A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator

Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if MSDC-0160 is effective in the treatment of Type 2 diabetes.
Phase:
Phase 2
Details
Lead Sponsor:
Metabolic Solutions Development Company
Treatments:
Pioglitazone